Harmony Biosciences
HRMY
146 hedge funds and large institutions have $1.9B invested in Harmony Biosciences in 2021 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 39 increasing their positions, 30 reducing their positions, and 14 closing their positions.
286% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 14
71% more capital inflows, than outflows
Capital inflows: $232M | Capital outflows: $136M
43% more funds holding
Funds holding: 102 → 146 (+44)
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
30% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 30
21.95% more ownership
Funds ownership: 54.26% → 76.21% (+22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$84.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$20.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.1M |
| 4 |
Janus Henderson Group
London,
|
+$12.9M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Newlight Partners
New York
|
-$39.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.6M |
| 3 |
venBio Partners
San Francisco,
California
|
-$12.9M |
| 4 |
Perceptive Advisors
New York
|
-$10M |
| 5 |
Aisling Capital Management
New York
|
-$9.46M |
HRMY Hedge Fund Activity: Q4 2021 in Review
146 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q4 2021, worth a combined $1.9B — up 60% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new HRMY positions and 14 closed out — a net gain of 40 holders — while 39 added to existing stakes and 30 trimmed.
The largest buyer was BlackRock, adding an estimated $84.7M. The largest seller was Newlight Partners, cutting an estimated $39.9M.
- 146 institutional investors held Harmony Biosciences (HRMY) as of Q4 2021, up from 102 in Q3 2021.
- Funds reported $1.9B of Harmony Biosciences stock for Q4 2021, up 60% quarter-over-quarter.
- 54 funds opened new Harmony Biosciences positions in Q4 2021 and 14 closed out, a net change of +40 holders.
- The largest Harmony Biosciences buyer in Q4 2021 was BlackRock, an estimated $84.7M added.
- The largest Harmony Biosciences seller in Q4 2021 was Newlight Partners, an estimated $39.9M sold.
Based on aggregated 13F filings for Q4 2021.